Table of Contents Author Guidelines Submit a Manuscript
Evidence-Based Complementary and Alternative Medicine
Volume 2013, Article ID 741985, 10 pages
http://dx.doi.org/10.1155/2013/741985
Research Article

JNK1/2 Activation by an Extract from the Roots of Morus alba L. Reduces the Viability of Multidrug-Resistant MCF-7/Dox Cells by Inhibiting YB-1-Dependent MDR1 Expression

Laboratory of Clinical Biology and Pharmacogenomics, Department of Preventive Medicine, College of Korean Medicine, Kyung Hee University, 1 Hoegi, Dongdaemun, Seoul 130-701, Republic of Korea

Received 5 April 2013; Revised 28 June 2013; Accepted 30 June 2013

Academic Editor: Bo-Hyoung Jang

Copyright © 2013 Youn Kyung Choi et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. C. R. Fairchild, J. A. Moscow, E. E. O'Brien, and K. H. Cowan, “Multidrug resistance in cells transfected with human genes encoding a variant P-glycoprotein and glutathione S-transferase-π,” Molecular Pharmacology, vol. 37, no. 6, pp. 801–809, 1990. View at Google Scholar · View at Scopus
  2. J. W. Jaroszewski, O. Kaplan, and J. S. Cohen, “Action of gossypol and rhodamine 123 on wild type and multidrug-resistant MCF-7 human breast cancer cells: 31P nuclear magnetic resonance and toxicity studies,” Cancer Research, vol. 50, no. 21, pp. 6936–6943, 1990. View at Google Scholar · View at Scopus
  3. L. J. Goldstein, H. Galski, A. Fojo et al., “Expression of a multidrug resistance gene in human cancers,” Journal of the National Cancer Institute, vol. 81, no. 2, pp. 116–124, 1989. View at Google Scholar · View at Scopus
  4. G. D. Leonard, T. Fojo, and S. E. Bates, “The role of ABC transporters in clinical practice,” Oncologist, vol. 8, no. 5, pp. 411–424, 2003. View at Publisher · View at Google Scholar · View at Scopus
  5. B. C. Shaffer, J.-P. Gillet, C. Patel, M. R. Baer, S. E. Bates, and M. M. Gottesman, “Drug resistance: still a daunting challenge to the successful treatment of AML,” Drug Resistance Updates, vol. 15, pp. 62–69, 2012. View at Publisher · View at Google Scholar · View at Scopus
  6. R. de Souza, P. Zahedi, R. M. Badame, C. Allen, and M. Piquette-Miller, “Chemotherapy dosing schedule influences drug resistance development in ovarian cancer,” Molecular Cancer Therapeutics, vol. 10, no. 7, pp. 1289–1299, 2011. View at Publisher · View at Google Scholar · View at Scopus
  7. A.-C. Hoffmann, P. Wild, C. Leicht et al., “MDR1 and ERCC1 expression predict outcome of patients with locally advanced bladder cancer receiving adjuvant chemotheraphy,” Neoplasia, vol. 12, no. 8, pp. 628–636, 2010. View at Publisher · View at Google Scholar · View at Scopus
  8. J. Bourhis, J. Benard, O. Hartmann, L. Boccon-Gibod, J. Lemerle, and G. Riou, “Correlation of MDR1 gene expression with chemotherapy in neuroblastoma,” Journal of the National Cancer Institute, vol. 81, no. 18, pp. 1401–1405, 1989. View at Google Scholar · View at Scopus
  9. R. C. Bargou, K. Jürchott, C. Wagener et al., “Nuclear localization and increased levels of transcription factor YB-1 in primary human breast cancers are associated with intrinsic MDR1 gene expression,” Nature Medicine, vol. 3, no. 4, pp. 447–450, 1997. View at Publisher · View at Google Scholar · View at Scopus
  10. Y. Basaki, F. Hosoi, Y. Oda et al., “Akt-dependent nuclear localization of Y-box-binding protein 1 in acquisition of malignant characteristics by human ovarian cancer cells,” Oncogene, vol. 26, no. 19, pp. 2736–2746, 2007. View at Publisher · View at Google Scholar · View at Scopus
  11. M. Kuwano, Y. Oda, H. Izumi et al., “The role of nuclear Y-box binding protein 1 as a global marker in drug resistance,” Molecular Cancer Therapeutics, vol. 3, no. 11, pp. 1485–1492, 2004. View at Google Scholar · View at Scopus
  12. T. Ohga, K. Koike, M. Ono et al., “Role of the human Y box-binding protein YB-1 in cellular sensitivity to the DNA-damaging agents cisplatin, mitomycin C, and ultraviolet light,” Cancer Research, vol. 56, no. 18, pp. 4224–4228, 1996. View at Google Scholar · View at Scopus
  13. V. Evdokimova, P. Ruzanov, M. S. Anglesio et al., “Akt-mediated YB-1 phosphorylation activates translation of silent mRNA species,” Molecular and Cellular Biology, vol. 26, no. 1, pp. 277–292, 2006. View at Publisher · View at Google Scholar · View at Scopus
  14. B. W. Sutherland, J. Kucab, J. Wu et al., “Akt phosphorylates the Y-box binding protein 1 at Ser102 located in the cold shock domain and affects the anchorage-independent growth of breast cancer cells,” Oncogene, vol. 24, no. 26, pp. 4281–4292, 2005. View at Publisher · View at Google Scholar · View at Scopus
  15. A. G. Bader, K. A. Felts, N. Jiang, H. W. Chang, and P. K. Vogt, “Y box-binding protein 1 induces resistance to oncogenic transformation by the phosphatidylinositol 3-kinase pathway,” Proceedings of the National Academy of Sciences of the United States of America, vol. 100, no. 21, pp. 12384–12389, 2003. View at Publisher · View at Google Scholar · View at Scopus
  16. G. Chen, B. A. Teicher, and E. Frei III, “Differential interactions of Pgp inhibitor thaliblastine with adriamycin, etoposide, taxol and anthrapyrazole CI941 in sensitive and multidrug-resistant human MCF-7 breast cancer cells,” Anticancer Research, vol. 16, no. 6, pp. 3499–3506, 1996. View at Google Scholar · View at Scopus
  17. J. Zhou, M. Liu, R. Aneja, R. Chandra, H. Lage, and H. C. Joshi, “Reversal of P-glycoprotein-mediated multidrug resistance in cancer cells by the c-Jun NH2-terminal kinase,” Cancer Research, vol. 66, no. 1, pp. 445–452, 2006. View at Publisher · View at Google Scholar · View at Scopus
  18. M. Liu, D. Li, R. Aneja et al., “PO2-dependent differential regulation of multidrug resistance 1 gene expression by the c-Jun NH2-terminal kinase pathway,” Journal of Biological Chemistry, vol. 282, no. 24, pp. 17581–17586, 2007. View at Publisher · View at Google Scholar · View at Scopus
  19. G. K. Chen, S. Sale, T. Tan, R. P. Ermoian, and B. I. Sikic, “CCAAT/enhancer-binding protein beta (nuclear factor for interleukin 6) transactivates the human MDR1 gene by interaction with an inverted CCAAT box in human cancer cells,” Molecular Pharmacology, vol. 65, no. 4, pp. 906–916, 2004. View at Publisher · View at Google Scholar · View at Scopus
  20. B. Ogretmen and A. R. Safa, “Negative regulation of MDR1 promoter activity in MCF-7, but not in multidrug resistant MCF-7/Adr, cells by cross-coupled NF-κb/p65 and c-Fos transcription factors and their interaction with the CAAT region,” Biochemistry, vol. 38, no. 7, pp. 2189–2199, 1999. View at Publisher · View at Google Scholar · View at Scopus
  21. S.-Y. Katoh, M. Ueno, and N. Takakura, “Involvement of MDR1 function in proliferation of tumour cells,” Journal of Biochemistry, vol. 143, no. 4, pp. 517–524, 2008. View at Publisher · View at Google Scholar · View at Scopus
  22. Y. Yamatake, M. Shibata, and M. Nagai, “Pharmacological studies on root bark of mulberry tree (Morus alba L.),” Japanese Journal of Pharmacology, vol. 26, no. 4, pp. 461–469, 1976. View at Google Scholar · View at Scopus
  23. S.-Y. Nam, H.-K. Yi, C. L. Jung et al., “Cortex Mori extract induces cancer cell apoptosis through inhibition of microtubule assembly,” Archives of Pharmacal Research, vol. 25, no. 2, pp. 191–196, 2002. View at Google Scholar · View at Scopus
  24. T. Kikuchi, M. Nihei, H. Nagai et al., “Albanol a from the root bark of Morus alba L. induces apoptotic cell death in HL60 human leukemia cell line,” Chemical and Pharmaceutical Bulletin, vol. 58, no. 4, pp. 568–571, 2010. View at Publisher · View at Google Scholar · View at Scopus
  25. S. Park, J. Kim, and Y. Kim, “Mulberry leaf extract inhibits cancer cell stemness in neuroblastoma,” Nutrition and Cancer, vol. 64, pp. 889–898, 2012. View at Publisher · View at Google Scholar
  26. Y. Yang, T. Gong, C. Liu, and R.-Y. Chen, “Four new 2-arylbenzofuran derivatives from leaves of Morus alba L.,” Chemical and Pharmaceutical Bulletin, vol. 58, no. 2, pp. 257–260, 2010. View at Publisher · View at Google Scholar · View at Scopus
  27. Y. Yang, T. Zhang, L. Xiao, L. Yang, and R. Chen, “Two new chalcones from leaves of Morus alba L.,” Fitoterapia, vol. 81, no. 6, pp. 614–616, 2010. View at Publisher · View at Google Scholar · View at Scopus
  28. M. Deepa and S. Priya, “Purification and characterization of a novel anti-proliferative lectin from Morus alba L. leaves,” Protein & Peptide Letters, vol. 19, pp. 839–845, 2012. View at Publisher · View at Google Scholar
  29. M. Deepa, T. Sureshkumar, P. K. Satheeshkumar, and S. Priya, “Purified mulberry leaf lectin (MLL) induces apoptosis and cell cycle arrest in human breast cancer and colon cancer cells,” Chemico-Biological Interactions, vol. 200, pp. 38–44, 2012. View at Publisher · View at Google Scholar
  30. Z. Hu, S. Jin, and K. W. Scotto, “Transcriptional activation of the MDR1 gene by UV irradiation: role of NF-Y and Sp1,” Journal of Biological Chemistry, vol. 275, no. 4, pp. 2979–2985, 2000. View at Publisher · View at Google Scholar · View at Scopus
  31. K. Nooter, A. M. Westerman, M. J. Flens et al., “Expression of the multidrug resistance-associated protein (MRP) gene in human cancers,” Clinical Cancer Research, vol. 1, no. 11, pp. 1301–1310, 1995. View at Google Scholar · View at Scopus
  32. T. Oue, A. Yoneda, S. Uehara, H. Yamanaka, and M. Fukuzawa, “Increased expression of multidrug resistance-associated genes after chemotherapy in pediatric solid malignancies,” Journal of Pediatric Surgery, vol. 44, no. 2, pp. 377–380, 2009. View at Publisher · View at Google Scholar · View at Scopus
  33. S. K. Wattanapitayakul, L. Chularojmontri, A. Herunsalee, S. Charuchongkolwongse, S. Niumsakul, and J. A. Bauer, “Screening of antioxidants from medicinal plants for cardioprotective effect against doxorubicin toxicity,” Basic and Clinical Pharmacology and Toxicology, vol. 96, no. 1, pp. 80–87, 2005. View at Publisher · View at Google Scholar · View at Scopus
  34. F. Yan, X.-M. Wang, Z.-C. Liu, C. Pan, S.-B. Yuan, and Q.-M. Ma, “JNK1, JNK2, and JNK3 are involved in P-glycoprotein-mediated multidrugresistance of hepatocellular carcinoma cells,” Hepatobiliary and Pancreatic Diseases International, vol. 9, no. 3, pp. 287–295, 2010. View at Google Scholar · View at Scopus
  35. P. M.-K. Tang, D.-M. Zhang, B. N.-H. Xuan et al., “Photodynamic therapy inhibits p-glycoprotein mediated multidrug resistance via JNK activation in human hepatocellular carcinoma using the photosensitizer pheophorbide a,” Molecular Cancer, vol. 8, article 56, 2009. View at Publisher · View at Google Scholar · View at Scopus
  36. H. Bark and C.-H. Choi, “Psc833, cyclosporine analogue, downregulates MDR1 expression by activating JNK/c-Jun/AP-1 and suppressing NF-κB,” Cancer Chemotherapy and Pharmacology, vol. 65, no. 6, pp. 1131–1136, 2010. View at Publisher · View at Google Scholar · View at Scopus
  37. K. Kawasaki, M. Watanabe, M. Sakaguchi et al., “REIC/Dkk-3 overexpression downregulates P-glycoprotein in multidrug-resistant MCF7/ADR cells and induces apoptosis in breast cancer,” Cancer Gene Therapy, vol. 16, no. 1, pp. 65–72, 2009. View at Publisher · View at Google Scholar · View at Scopus
  38. Z.-H. Miao and J. Ding, “Transcription factor c-Jun activation represses mdr-1 gene expression,” Cancer Research, vol. 63, no. 15, pp. 4527–4532, 2003. View at Google Scholar · View at Scopus
  39. K. M. Comerford, E. P. Cummins, and C. T. Taylor, “c-Jun NH2-terminal kinase activation contributes to hypoxia-inducible factor 1α-dependent P-glycoprotein expression in hypoxia,” Cancer Research, vol. 64, no. 24, pp. 9057–9061, 2004. View at Publisher · View at Google Scholar · View at Scopus
  40. H. Sui, S. Zhou, Y. Wang et al., “COX-2 contributes to P-glycoprotein-mediated multidrug resistance via phosphorylation of c-Jun at Ser63/73 in colorectal cancer,” Carcinogenesis, vol. 32, no. 5, pp. 667–675, 2011. View at Publisher · View at Google Scholar · View at Scopus